PMEF
WVE icon

Point72 Middle East FZE’s Wave Life Sciences WVE Stock Holding History

Point72 Middle East FZE’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,601
Closed -$54.6K – 2112
2023
Q1 		$54.6K Buy
+12,601
New +$57.7K ﹤0.01% 1254

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Point72 Middle East FZE's WVE Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Wave Life Sciences (WVE) in Q2 2023, closing a stake of 12,601 shares — an estimated $54.6K sold.

Point72 Middle East FZE first reported a position in WVE in Q1 2023 and held it in 1 quarter. The position peaked at $54.6K in Q1 2023. 81 funds tracked by Wall St. Rank hold WVE as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Wave Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 12,601 Wave Life Sciences shares in Q2 2023, an estimated $54.6K.
  • Point72 Middle East FZE first reported a position in Wave Life Sciences in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Wave Life Sciences position peaked at $54.6K in Q1 2023.
  • 81 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.